Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: August 17, 2017
What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?
ABBVIE has eighty-eight approved drugs.| Patents: | 86 |
| Tradenames: | 77 |
| Ingredients: | 64 |
| NDAs: | 88 |
| Drug Master File Entries: (click here to view) | 1 |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Inc | NORVIR | ritonavir | POWDER;ORAL | 209512-001 | Jun 7, 2017 | RX | Yes | Yes | ► Subscribe | ► Subscribe | ► Subscribe | ||||||||||||||||||
Abbvie | NORVIR | ritonavir | TABLET;ORAL | 022417-001 | Feb 10, 2010 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
Abbvie | TRICOR | fenofibrate | TABLET;ORAL | 021656-002 | Nov 5, 2004 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
Abbvie | CALCIJEX | calcitriol | INJECTABLE;INJECTION | 018874-002 | Sep 25, 1986 | DISCN | Yes | No | ► Subscribe | ► Subscribe | Y | ► Subscribe | |||||||||||||||||
Abbvie | DEPAKOTE ER | divalproex sodium | TABLET, EXTENDED RELEASE;ORAL | 021168-001 | Aug 4, 2000 | AB | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | ► Subscribe | ||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 019732-001 | Jan 26, 1989 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020708-001 | Mar 7, 1997 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-002 | May 30, 1997 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbvie | ZEMPLAR | paricalcitol | CAPSULE;ORAL | 021606-003 | May 26, 2005 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
Abbvie Endocrine Inc | LUPRON DEPOT | leuprolide acetate | INJECTABLE;INJECTION | 020517-001 | Dec 22, 1995 | ► Subscribe | ► Subscribe | ||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
lopinavir and ritonavir | Oral Solution | 80 mg/20 mg per mL | KALETRA | 6/19/2014 |
testosterone | Gel | 1.62% (1.25 g and 2.5 g packets) | ANDROGEL | 6/19/2013 |
ritonavir | Capsules | 100 mg | NORVIR | 10/31/2012 |
testosterone | Gel | 1.62% | ANDROGEL | 4/6/2012 |
ritonavir | Tablets | 100 mg | NORVIR | 12/21/2010 |
clarithromycin | Extended-release Tablet | 500 mg | BIAXIN XL | 12/6/2010 |
eprosartan mesylate | Tablets | 400 mg and 600 mg | TEVETEN | 5/10/2010 |
fenofibrate choline | Delayed-release Capsules | 45 mg | TRILIPIX | 9/2/2009 |
fenofibrate choline | Delayed-release Capsules | 135 mg | TRILIPIX | 9/1/2009 |
cisatracurium besylate (multi-dose) | Injection | 2 mg/mL, 10 mL vial | NIMBEX | 8/12/2009 |
cisatracurium besylate (preserve free) | Injection | 2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial | NIMBEX | 8/4/2009 |
lopinavir and ritonavir | Tablets | 100 mg/25 mg | KALETRA | 12/23/2008 |
testosterone | Gel Metered-dose Pump | 1% | ANDROGEL | 12/19/2008 |
paricalcitol | Injection | 0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials | ZEMPLAR | 11/28/2008 |
paricalcitol | Capsules | 1 mcg and 2 mcg | ZEMPLAR | 10/14/2008 |
paricalcitol | Capsules | 4 mcg | ZEMPLAR | 8/25/2008 |
fenofibrate | Tablets | 48 mg | TRICOR | 7/1/2008 |
trandolapril and verapamil hydrochloride | Extended-release Tablets | 1 mg/240 mg | TARKA | 2/20/2008 |
trandolapril and verapamil hydrochloride | Extended-release Tablets | 2 mg/180 mg and 2 mg/240 mg | TARKA | 11/9/2007 |
fenofibrate | Tablets | 145 mg | TRICOR | 10/19/2007 |
trandolapril and verapamil hydrochloride | Extended-release Tablets | 4 mg/ 240 mg | TARKA | 7/24/2007 |
hydrocodone bitartrate and ibuprofen | Tablets | 2.5 mg/200 mg | VICOPROFEN | 2/24/2006 |
hydrocodone bitartrate and ibuprofen | Tablets | 5 mg/200 mg | VICOPROFEN | 5/27/2005 |
divalproex sodium | Extended-release Tablets | 500 mg | DEPAKOTE ER | 2/8/2005 |
trandolapril | Tablets | 1 mg, 2 mg and 4 mg | MAVIK | 10/4/2004 |
divalproex sodium | Extended-release Tablets | 250 mg | DEPAKOTE ER | 5/3/2004 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6,428,814 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers | ► Subscribe | |||||||||||||||||||||||||||
| 6,558,679 | Container for an inhalation anesthetic | ► Subscribe | |||||||||||||||||||||||||||
| 7,288,267 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers | ► Subscribe | |||||||||||||||||||||||||||
| 9,034,875 | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | ► Subscribe | |||||||||||||||||||||||||||
| 8,937,150 | Anti-viral compounds | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom | 201400676 | ► Subscribe | |||||||||||||||||||||||||||
| Canada | 2341805 | ► Subscribe | |||||||||||||||||||||||||||
| Cyprus | 1116728 | ► Subscribe | |||||||||||||||||||||||||||
| Japan | 2010018604 | ► Subscribe | |||||||||||||||||||||||||||
| Israel | 154668 | ► Subscribe | |||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C/GB98/040 | United Kingdom | ► Subscribe | PRODUCT NAME: RABEPRAZOLE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE SODIUM SALT; REGISTERED: UK 10555/0010 19980508; UK 10555/0008 19980508 | ||||||||||||||||||||||||||
| 0731 | Netherlands | ► Subscribe | PRODUCT NAME: OMBITASVIR OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT DAARVAN; REGISTRATION NO/DATE: EU/1/14/982 20150119 | ||||||||||||||||||||||||||
| C0026 | France | ► Subscribe | PRODUCT NAME: RALTEGRAVIR OU L(UN DE SES SELS PHARMACEUTIQUEMENT ACCCEPTABLES EN PARTICULIER UN SEL DE POTASSIUM; REGISTRATION NO/DATE IN FRANCE: EU/1/07/436/001 DU 20071220; REGISTRATION NO/DATE AT EEC: EU/1/07/436/001 DU 20071220 | ||||||||||||||||||||||||||
| 2015 00015 | Denmark | ► Subscribe | PRODUCT NAME: OMBITASVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEROF; REG. NO/DATE: EU/1/14/982 20150119 | ||||||||||||||||||||||||||
| 12/008 | Ireland | ► Subscribe | PRODUCT NAME: AZILSARTAN MEDOXOMIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, INCLUDING THE POTASSIUM SALT; REGISTRATION NO/DATE: EU/1/11/734/001-011 EU/1/11/735/001-011 20111209 | ||||||||||||||||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,322 others who get our Drug Patent Expiration Alerts:
